CVRM Innovative Technologies Webinar
As the cardiovascular, renal and metabolic (CVRM) drug development landscape becomes increasingly interconnected and competitive, emerging technologies and innovative development strategies are creating new opportunities to accelerate research, improve clinical outcomes and differentiate therapeutic pipelines.
Join Kenny Lalwani, Founder and CEO of NeoKardia, for an expert-led webinar exploring how technological advancements, evolving clinical trial approaches and data-driven strategies are reshaping drug development across cardiovascular disease, obesity and type 2 diabetes.
From improving cardiovascular outcomes and obesity innovation to unlocking the potential of precision medicine, this session will examine the technologies and strategic considerations influencing the next generation of CVRM therapies.
Discover how developers can navigate increasing clinical complexity, identify meaningful opportunities for differentiation and make more informed decisions in a rapidly evolving therapeutic landscape.
Register now to explore the innovations shaping the future of CVRM drug development.
Register Now
Please complete the form to register for the webinar.
Key Insights:
1. Advancing Cardiovascular Outcomes Trials
Explore how emerging technologies are transforming the design, monitoring and interpretation of cardiovascular outcomes trials, supporting more effective clinical development strategies.
2. Driving Differentiation in Obesity Drug Development
Understand how developers can identify meaningful therapeutic differentiation and competitive opportunities as the obesity treatment landscape becomes increasingly crowded.
3. Expanding Innovation in Type 2 Diabetes
Discover emerging approaches to evaluating broader cardiometabolic benefits and organ-protective effects, and their implications for future therapeutic development.
4. Unlocking the Potential of Precision Medicine
Examine the technologies and data-driven strategies that could make precision medicine more practical and impactful across cardiovascular, renal and metabolic diseases.
5. Optimising Clinical Trial Design and Execution
Learn how innovative trial technologies and development approaches can help address challenges in patient recruitment, retention and study execution.
About the Speaker
Kenny Lalwani is the Founder and CEO of NeoKardia, a biotechnology company focused on developing innovative therapies for cardiovascular and renal diseases.
With over a decade of experience across the pharmaceutical and biotechnology industries, Kenny brings extensive expertise in corporate development, pipeline strategy, clinical and commercial assessments, and portfolio optimisation
Previously, Kenny held senior leadership positions at Viridian Therapeutics and Gilead Sciences, where he contributed to R&D strategy, therapeutic opportunity assessments and clinical and commercial decision-making.
He has also advised global pharmaceutical organisations on commercialisation and portfolio strategy at QuintilesIMS and founded Obsidian Sciences, a biotechnology advisory firm.
Combining scientific understanding with commercial and strategic expertise, Kenny brings a valuable industry perspective on the opportunities and challenges shaping CVRM drug development.
Don’t miss this opportunity to explore the innovations and strategic approaches shaping the next generation of CVRM drug development.
Webinar Leader
Kenny Lalwani
Founder & CEO at NeoKardia, Inc.
Andy Williams
Director of Data Products at Beacon
You May Also Be Interested In…
Learn More About CVRM
- The Most Comprehensive Way to Search the CVRM Drug Development Landscape: Unique search ontologies based on CVRM drug and trial characteristics
- Market Leading Approach to CVRM Preclinical & Clinical Data Curation: Manual curation of key CVRM research and development data points by CVRM research scientists
- Seamlessly Integrate Commercial & Scientific Data all in One Place: Search CVRM company and deal data based on their pipeline and technologies.
- Unrivalled Granularity in Reports & Analysis: Our search ontology and technology indexing enable comprehensive analysis not seen elsewhere.
What is Beacon?
Beacon is the essential intelligence platform for R&D decision-makers working in pharma and biotech, offering unique technology and drug datasets for complex therapeutics and disease areas.
Our market-defining proprietary ontologies, manual data curation, and accurate and comprehensive life science data, provide our customers with unparalleled visibility of the drug, trial and commercial landscape.
This is why 24 of the top 25 pharmaceutical companies trust Beacon to power their critical pipeline, competitive, and commercial decisions.
We’d welcome the opportunity to show you how Beacon can transform your data strategy. Book your personalized demonstration today!